Synapse - Dana Rathkopf

Results (275)

Phase 3 MAGNITUDE study: Results from second interim analysis of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without HRR gene alteration

Meeting Abstract

Rathkopf, D. E.; Small, E.; Guckert, M.; Chi, K. N.
Oncology Nursing Forum (2023)

Fulltext@MSK | Save

Patients receiving short run-in treatment (≤2 months) with abiraterone acetate and prednisone (AAP) showed similar benefit from niraparib and AAP in the phase 3 MAGNITUDE study with metastatic castration-resistant prostate cancer and HRR gene alterations

Meeting Abstract

Smith, M.; Efstathiou, E.; Rathkopf, D. E.; Guckert, M.; Chi, K. N.
Oncology Nursing Forum (2023)

Fulltext@MSK | Save

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Journal Article

Gillessen, S.; Bossi, A.; Davis, I. D.; de Bono, J.; Fizazi, K.; James, N. D.; Mottet, N.; Shore, N.; Small, E.; Smith, M.; more...
European Journal of Cancer (2023)

Fulltext@MSK | Save

A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer

Meeting Abstract

Bryce, A. H.; Karp, D. D.; Tagawa, S. T.; Nordquist, L. T.; Rathkopf, D. E.; Adra, N.; Dorff, T. B.; Baeck, J.; O'Donnell, J. F.; Ames, T. D.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)

Meeting Abstract

Nguyen, P. L.; Kollmeier, M.; Rathkopf, D. E.; Hoffman, K. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer

Meeting Abstract

Mucci, L. A.; Vinson, J.; Gerke, T. A.; Hyslop, T.; Howard, L.; Dreicer, R.; Rathkopf, D. E.; Chi, K. N.; Esteban, E.; Enting, D.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE

Meeting Abstract

Efstathiou, E.; Smith, M. R.; Sandhu, S.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Gomes, A. J.; Small, E. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Meeting Abstract

Castro, E.; Chi, K. N.; Sandhu, S.; Olmos, D.; Attard, G.; Saad, M.; Gomes, A. J.; Rathkopf, D. E.; Smith, M. R.; Kang, T. W.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Management of patients with advanced prostate cancer. Part I: Intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022